> top > docs > PMC:7195088 > spans > 22875-23181 > annotations

PMC:7195088 / 22875-23181 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
680 142-150 Species denotes patients Tax:9606
681 193-201 Species denotes patients Tax:9606
682 275-283 Species denotes patients Tax:9606
813 0-11 Chemical denotes Favipiravir MESH:C462182
814 164-175 Chemical denotes favipiravir MESH:C462182
815 212-222 Chemical denotes umifenovir MESH:C086979
816 294-305 Chemical denotes favipiravir MESH:C462182
947 133-141 Disease denotes COVID-19 MESH:C000657245
948 184-192 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T20 27-30 Body_part denotes RNA http://purl.org/sig/ont/fma/fma67095
T21 41-44 Body_part denotes RNA http://purl.org/sig/ont/fma/fma67095

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T111 17-26 Disease denotes influenza http://purl.obolibrary.org/obo/MONDO_0005812
T112 133-141 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T113 184-192 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T112 71-72 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T113 97-98 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T270 41-65 Chemical denotes RNA polymerase inhibitor http://purl.obolibrary.org/obo/CHEBI_37416
T271 56-65 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T272 164-175 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722
T273 212-222 Chemical denotes umifenovir http://purl.obolibrary.org/obo/CHEBI_134730
T274 294-305 Chemical denotes favipiravir http://purl.obolibrary.org/obo/CHEBI_134722

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T170 0-306 Sentence denotes Favipiravir Anti-influenza RNA-dependent RNA polymerase inhibitor • In a recent RCT published on a preprint server and comparing 120 COVID-19 patients treated with favipiravir vs. 120 COVID-19 patients receiving umifenovir, higher rates of clinical recovery were observed in patients receiving favipiravir.